Loading…
Loading…
Medpace (MEDP) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago.
Medpace stock surged by double digits late Wednesday helped by a big bookings beat.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
On July 07, 2026, Medpace Holdings Inc (MEDP) shares fell 3.4% today to a current price of $546.29. The stock has experienced significant volatility, trading wi
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for MEDP and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.